Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
The present hypothesis is that anti-EGFR agents are active in tumors with low-level RAS
mutation when the majority of tumor cells is still sensitive. While response rate may be high
and may reflect sensitivity to anti-EGFR agents, PFS is anticipated to be shorter than in RAS
wild-type patients due to the faster development of resistance when sensitive cells are
eradicated and when the RAS-mutant anti-EGFR resistant clones become predominant.
The characteristics of low-level RAS mutant tumors would be:
- Objective response rate (ORR) high (reflecting the sensitive clone)
- Progression-free survival (PFS) short (reflecting the more rapid outgrowth of RAS mutant
clones)